A Phase III Study of CS1001 in Combination With FP in Subjects With Esophageal Squamous Cell Carcinoma
Condition: Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: CS1001+ Fluorouracil+Cisplatin; Drug: Placebo+ Fluorouracil+Cisplatin Sponsor: CStone Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Esophagus Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study